A chronic disappointment for Viridian

At first glance the topline six-week data on Viridian’s VRDN-001 in chronic thyroid eye disease, released last night, make the anti-IGF-1R MAb look competitive with Horizon’s Tepezza. But Viridian did not release full placebo results, meaning any cross-trial comparison – always an imperfect metric – comes with even more caveats.